About Linical
Linical is a company based in Osaka (Japan) founded in 2005. Linical has completed 1 acquisition, including Accelovance. Linical operates in a competitive market with competitors including Helsinn, Aster Insights, Abogen Biosciences, OnCusp and CancerVax, among others.
- Headquarter Osaka, Japan
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Linical Co., Ltd.
-
Annual Revenue
$69.86 M (USD)-15.2as on Mar 31, 2025
-
Net Profit
-$3.61 M (USD)-259.37as on Mar 31, 2025
-
EBITDA
-$311.18 K (USD)-103.73as on Mar 31, 2025
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Linical
Linical is a publicly listed company on the TSE with ticker symbol 2183 in Japan, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Linical
Unlock access to complete
Leadership Team
12 people
Clinical Team
5 people
Human Resources and Administration
4 people
Operations Team
3 people
Finance and Accounting
3 people
Sales and Marketing
3 people
Data Analysis and Operations Team
2 people
Legal and Compliance
2 people
Unlock access to complete
Funding Insights of Linical
Detailed funding history for Linical
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Linical
Linical has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Accelovance.
Investment portfolio details for Linical
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
CRO specializing in Phase I-IV programs of Vaccines, Early Phase Oncology, and General medicine
|
Locked | Locked | 2005 | Locked |
Complete acquisition details for Linical
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Linical
Detailed financials for Linical
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Linical Comparisons
Peer comparison for Linical
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Linical
Linical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Helsinn, Aster Insights, Abogen Biosciences, OnCusp and CancerVax, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Oncology therapeutics are developed, manufactured, and commercialized by Helsinn.
|
|
| Locked | Locked | Locked |
Contract-based oncology clinical trial services are provided by Aster Insights.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics are developed for cancer and infectious diseases.
|
|
| Locked | Locked | Locked |
CRO offering clinical development services for oncology drugs
|
|
| Locked | Locked | Locked |
Cancer vaccine research and development is conducted by CancerVax.
|
Detailed competitors of Linical
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Linical
Complete news archive for Linical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Linical
Linical was founded in 2005.
Linical is headquartered in Osaka, Japan. It is registered at Osaka, Osaka Prefecture, Japan.
Keigo Tsujimoto is the current CEO of Linical.
Annual revenue of Linical is $69.86M as on Mar 31, 2025.
Linical is a full-service CRO, headquartered in Japan and operations in 20 countries which includes all major markets in the Asia-Pacific, North American and European regions. Their service portfolio includes project management, clinical monitoring, data management, statistical analysis, medical writing, pharmacovigilance, regulatory affairs, medical management. They offer their clinical trial services in a wide range of therapeutic areas and claim to have expertise in oncology, CNS, immunology, respiratory, allergy, endocrinology and GI disorders.
Yes, Linical is publicly traded on TSE under the ticker symbol 2183.
Linical has made 1 acquisition, including Accelovance.
The ticker symbol of Linical is 2183 on TSE.